{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["avelumab","talazoparib"]],"indication":"locally advanced or metastatic solid tumors","name":"JAVELIN PARP MEDLEY","nct_id":"NCT03330405","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=javelin-parp-medley-nct03330405. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Drug: Avelumab\n\nDrug: Talazoparib","label":"Dose Level 0 Phase 1b","type":"EXPERIMENTAL"},{"description":"Drug: Avelumab\n\nDrug: Talazoparib","label":"Dose Level -1 Phase 1b","type":"EXPERIMENTAL"},{"description":"Drug: Avelumab\n\nDrug: Talazoparib","label":"Dose Level -2 Phase 1b","type":"EXPERIMENTAL"},{"description":"Drug: Avelumab\n\nDrug: Talazoparib","label":"A1. NSCLC Phase 2","type":"EXPERIMENTAL"},{"description":"Drug: Avelumab\n\nDrug: Talazoparib","label":"A2. NSCLC PD-L1 Resistant DDR+ Phase 2","type":"EXPERIMENTAL"},{"description":"Drug: Avelumab\n\nDrug: Talazoparib","label":"B1. TNBC Phase 2","type":"EXPERIMENTAL"},{"description":"Drug: Avelumab\n\nDrug: Talazoparib","label":"B2. HR+BC DDR Defect +Assay Phase 2","type":"EXPERIMENTAL"},{"description":"Drug: Avelumab\n\nDrug: Talazoparib","label":"C1. Ovarian CA Recurrent Plat-Sensitive Phase 2","type":"EXPERIMENTAL"},{"description":"Drug: Avelumab\n\nDrug: Talazoparib","label":"C2.Ovarian CA Recurrent Plat-Sensitive BRCA defect Phase 2","type":"EXPERIMENTAL"},{"description":"Drug: Avelumab\n\nDrug: Talazoparib","label":"D.Urothelial CA Phase 2","type":"EXPERIMENTAL"},{"description":"Drug: Avelumab\n\nDrug: Talazoparib","label":"E1. CRPC Phase 2","type":"EXPERIMENTAL"},{"description":"Drug: Avelumab\n\nDrug: Talazoparib","label":"E2. CRPC DDR Defect +Assay Phase 2","type":"EXPERIMENTAL"},{"description":"Drug: Avelumab\n\nDrug: Talazoparib","label":"F: Advanced Solid Tumors with BRCA or ATM defect Phase 2","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-01-04","type":"ACTUAL"},"conditions":["Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors"],"enrollment":{"count":223,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Avelumab Phase 1b","otherNames":["MSB0010718C"],"type":"DRUG"},{"name":"Talazoparib Phase 1b","otherNames":["MDV3800, BMN 673"],"type":"DRUG"},{"name":"Avelumab Phase 2","otherNames":["MSB0010718C"],"type":"DRUG"},{"name":"Talazoparib Phase 2","otherNames":["MDV3800, BMN 673"],"type":"DRUG"}],"last_update":"2023-10-13","lead_sponsor":"Pfizer","official_title":"A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY(ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2022-02-22","type":"ACTUAL"},"primary_outcomes":[{"measure":"Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs)","timeFrame":"Cycle 1; 28 days"},{"measure":"Phase 2: Percentage of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment","timeFrame":"From start of the treatment until disease progression or death due to any cause, whichever occurred first (maximum up to 4.3 years approximately)"},{"measure":"Phase 2: Percentage of Participants With Confirmed Objective Response (OR) as Per RECIST v1.1 and Prostate Cancer Working Group 3 (PCWG3) by Investigator Assessment","timeFrame":"From start of the treatment until disease progression or death due to any cause, whichever occurred first (maximum up to 4.3 years approximately)"}],"references":[{"citation":"Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Wise DR, Karyakin O, Rubovszky G, Kislov N, Rohrberg K, Joy AA, Telli ML, Schram AM, Conte U, Chappey C, Stewart R, Stypinski D, Michelon E, Cesari R, Konstantinopoulos PA. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial. JAMA Oncol. 2023 Jan 1;9(1):40-50. doi: 10.1001/jamaoncol.2022.5228.","pmid":"36394849","type":"DERIVED"}],"start_date":{"date":"2017-10-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors","url":"https://clinicaltrials.gov/study/NCT03330405"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/javelin-parp-medley-nct03330405"}